|
1
|
Yang J and Zhang W: New molecular insights
into osteosarcoma targeted therapy. Curr Opin Oncol. 25:398–406.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yu W, Zhu J, Wang Y, Wang J, Fang W, Xia
K, Shao J, Wu M, Liu B, Liang C, et al: A review and outlook in the
treatment of osteosarcoma and other deep tumors with photodynamic
therapy: From basic to deep. Oncotarget. 8:39833–39848.
2017.PubMed/NCBI
|
|
3
|
Berner K, Johannesen TB, Berner A,
Haugland HK, Bjerkehagen B, Bøhler PJ and Bruland OS: Time-trends
on incidence and survival in a nationwide and unselected cohort of
patients with skeletal osteosarcoma. Acta Oncol. 54:25–33. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Taran SJ, Taran R and Malipatil NB:
Pediatric osteosarcoma: An updated review. Indian J Med Paediatr
Oncol. 38:33–43. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Faisham WI, Mat Saad AZ, Alsaigh LN, Nor
Azman MZ, Kamarul Imran M, Biswal BM, Bhavaraju VM, Salzihan MS,
Hasnan J, Ezane AM, et al: Prognostic factors and survival rate of
osteosarcoma: A single-institution study. Asia Pac J Clin Oncol.
13:e104–e110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang S, Zheng S, Hu K, Sun H, Zhang J,
Rong G, Gao J, Ding N and Gui B: A predictive model to estimate the
pretest probability of metastasis in patients with osteosarcoma.
Medicine (Baltimore). 96:e59092017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sonkoly E: The expanding microRNA world in
psoriasis. Exp Dermatol. 26:375–376. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mellis D and Caporali A: MicroRNA-based
therapeutics in cardiovascular disease: Screening and delivery to
the target. Biochem Soc Trans. 46:11–21. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Acunzo M and Croce CM: MicroRNA in cancer
and cachexia-A mini-review. J Infect Dis. 212 (Suppl 1):S74–S77.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhai L, Li Y, Lan X and Ai L:
MicroRNA-10a-5p suppresses cancer proliferation and division in
human cervical cancer by targeting BDNF. Exp Ther Med.
14:6147–6151. 2017.PubMed/NCBI
|
|
12
|
Penna E, Orso F, Cimino D, Tenaglia E,
Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De
Pittà C, et al: microRNA-214 contributes to melanoma tumour
progression through suppression of TFAP2C. EMBO J. 30:1990–2007.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou T, Zhang GJ, Zhou H, Xiao HX and Li
Y: Overexpression of microRNA-183 in human colorectal cancer and
its clinical significance. Eur J Gastroenterol Hepatol. 26:229–233.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo P, Lan J, Ge J, Nie Q, Mao Q and Qiu
Y: miR-708 acts as a tumor suppressor in human glioblastoma cells.
Oncol Rep. 30:870–876. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rubie C, Kölsch K, Halajda B, Eichler H,
Wagenpfeil S, Roemer K and Glanemann M: microRNA-496-A new,
potentially aging-relevant regulator of mTOR. Cell Cycle.
15:1108–1116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu J, Liu T, Zhang Z, Xu Y and Zhu F:
Oxidized low-density lipoprotein promotes vascular endothelial cell
dysfunction by stimulating miR-496 expression and inhibiting the
Hippo pathway effector YAP. Cell Biol Int. 43:528–538. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cates JMM: Simple staging system for
osteosarcoma performs equivalently to the AJCC and MSTS systems. J
Orthop Res. 36:2802–2808. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Acunzo M, Romano G, Wernicke D and Croce
CM: MicroRNA and cancer-a brief overview. Adv Biol Regul. 57:1–9.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Palmini G, Marini F and Brandi ML: What is
new in the miRNA world regarding osteosarcoma and chondrosarcoma?
Molecules. 22(pii): E4172017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jianwei Z, Fan L, Xiancheng L, Enzhong B,
Shuai L and Can L: MicroRNA 181a improves proliferation and
invasion, suppresses apoptosis of osteosarcoma cell. Tumour Biol.
34:3331–3337. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen X, Lv C, Zhu X, Lin W, Wang L, Huang
Z, Yang S and Sun J: MicroRNA-504 modulates osteosarcoma cell
chemoresistance to cisplatin by targeting p53. Oncol Lett.
17:1664–1674. 2019.PubMed/NCBI
|
|
23
|
Ren J, Yang M, Xu F and Chen J:
microRNA-758 inhibits the malignant phenotype of osteosarcoma cells
by directly targeting HMGA1 and deactivating the Wnt/β-catenin
pathway. Am J Cancer Res. 9:36–52. 2019.PubMed/NCBI
|
|
24
|
Zhu XB, Zhang ZC, Han GS, Han JZ and Qiu
DP: Overexpression of miR-214 promotes the progression of human
osteosarcoma by regulating the Wnt/β-catenin signaling pathway. Mol
Med Rep. 15:1884–1892. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun X, Dai G, Yu L, Hu Q, Chen J and Guo
W: miR-143-3p inhibits the proliferation, migration and invasion in
osteosarcoma by targeting FOSL2. Sci Rep. 8:6062018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miao J, Wu S, Peng Z, Tania M and Zhang C:
MicroRNAs in osteosarcoma: Diagnostic and therapeutic aspects.
Tumour Biol. 34:2093–2098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mason D, Zhang X, Marques TM, Rose B,
Khoury S, Hill M, Deutsch F, Lyons JG, Gama-Carvalho M and Tran N:
Human papillomavirus 16 E6 modulates the expression of miR-496 in
oropharyngeal cancer. Virology. 521:149–157. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yao X, Yao R, Yi J and Huang F:
Upregulation of miR-496 decreases cerebral ischemia/reperfusion
injury by negatively regulating BCL2L14. Neurosci Lett.
696:197–205. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rubie C, Zimmer J, Lammert F, Gross JC,
Weber SN, Kruse B, Halajda B, Wagner M, Wagenpfeil S and Glanemann
M: MicroRNA-496 and mechanistic target of rapamycin expression are
associated with type 2 diabetes mellitus and obesity in elderly
people. Ann Nutr Metab. 74:279–286. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang J and Chen L: IL-1β inhibits
osteogenesis of human bone marrow-derived mesenchymal stem cells by
activating FoxD3/microRNA-496 to repress wnt signaling. Genesis.
55:2017. View Article : Google Scholar
|
|
31
|
Mariga A, Mitre M and Chao MV:
Consequences of brain-derived neurotrophic factor withdrawal in CNS
neurons and implications in disease. Neurobiol Dis. 97:73–79. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cao L, Liu X, Lin EJ, Wang C, Choi EY,
Riban V, Lin B and During MJ: Environmental and genetic activation
of a brain-adipocyte BDNF/leptin axis causes cancer remission and
inhibition. Cell. 142:52–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu X, McMurphy T, Xiao R, Slater A, Huang
W and Cao L: Hypothalamic gene transfer of BDNF inhibits breast
cancer progression and metastasis in middle age obese mice. Mol
Ther. 22:1275–1284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qi NN, Tian S, Li X, Wang FL and Liu B:
Up-regulation of microRNA-496 suppresses proliferation, invasion,
migration and in vivo tumorigenicity of human osteosarcoma cells by
targeting eIF4E. Biochimie. 163:1–11. 2019. View Article : Google Scholar : PubMed/NCBI
|
